Sensei Biotherapeutics, Inc. (SNSE), a clinical-stage biotechnology company, on Wednesday provided an update on its lead program, solnerstotug or SNS-101, an innovative antibody targeting the VISTA immune checkpoint in cancer immunotherapy.
Key updates include:
-- Sensei is advancing its multi-center Phase 1/2 clinical trial to evaluate solnerstotug or SNS-101 as both a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo or cemiplimab.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.